Breast Cancer - Pipeline Review, H1 2016

  • ID: 3802784
  • Report
  • 3011 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences, Inc.
  • Biocon Limited
  • EnzymeBioSystems
  • ISU ABXIS Co.,Ltd.
  • Oncolix, Inc.
  • Sellas Inc.
  • MORE
Breast Cancer - Pipeline Review, H1 2016

Summary

‘Breast Cancer - Pipeline Review, H1 2016’, provides an overview of the Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects
- The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Breast Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences, Inc.
  • Biocon Limited
  • EnzymeBioSystems
  • ISU ABXIS Co.,Ltd.
  • Oncolix, Inc.
  • Sellas Inc.
  • MORE
Introduction

Breast Cancer Overview

Therapeutics Development

Breast Cancer - Therapeutics under Development by Companies

Breast Cancer - Therapeutics under Investigation by Universities/Institutes

Breast Cancer - Pipeline Products Glance

Breast Cancer - Products under Development by Companies

Breast Cancer - Products under Investigation by Universities/Institutes

Breast Cancer - Companies Involved in Therapeutics Development

Breast Cancer - Therapeutics Assessment

Drug Profiles

Breast Cancer - Dormant Projects

Breast Cancer - Discontinued Products

Breast Cancer - Product Development Milestones

Appendix 2893List of Tables

Number of Products under Development for Breast Cancer, H1 2016

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)

Number of Products under Development by Companies, H1 2016 (Contd..9)

Number of Products under Development by Companies, H1 2016 (Contd..10)

Number of Products under Development by Companies, H1 2016 (Contd..11)

Number of Products under Development by Companies, H1 2016 (Contd..12)

Number of Products under Development by Companies, H1 2016 (Contd..13)

Number of Products under Development by Companies, H1 2016 (Contd..14)

Number of Products under Development by Companies, H1 2016 (Contd..15)

Number of Products under Development by Companies, H1 2016 (Contd..16)

Number of Products under Development by Companies, H1 2016 (Contd..17)

Number of Products under Development by Companies, H1 2016 (Contd..18)

Number of Products under Development by Companies, H1 2016 (Contd..19)

Number of Products under Development by Companies, H1 2016 (Contd..20)

Number of Products under Development by Companies, H1 2016 (Contd..21)

Number of Products under Development by Companies, H1 2016 (Contd..22)

Number of Products under Development by Companies, H1 2016 (Contd..23)

Number of Products under Development by Companies, H1 2016 (Contd..24)

Number of Products under Development by Companies, H1 2016 (Contd..25)

Number of Products under Development by Companies, H1 2016 (Contd..26)

Number of Products under Development by Companies, H1 2016 (Contd..27)

Number of Products under Development by Companies, H1 2016 (Contd..28)

Number of Products under Development by Companies, H1 2016 (Contd..29)

Number of Products under Development by Companies, H1 2016 (Contd..30)

Number of Products under Development by Companies, H1 2016 (Contd..31)

Number of Products under Development by Companies, H1 2016 (Contd..32)

Number of Products under Development by Companies, H1 2016 (Contd..33)

Number of Products under Development by Companies, H1 2016 (Contd..34)

Number of Products under Development by Companies, H1 2016 (Contd..35)

Number of Products under Development by Companies, H1 2016 (Contd..36)

Number of Products under Development by Companies, H1 2016 (Contd..37)

Number of Products under Development by Companies, H1 2016 (Contd..38)

Number of Products under Investigation by Universities/Institutes, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Products under Development by Companies, H1 2016 (Contd..12)

Products under Development by Companies, H1 2016 (Contd..13)

Products under Development by Companies, H1 2016 (Contd..14)

Products under Development by Companies, H1 2016 (Contd..15)

Products under Development by Companies, H1 2016 (Contd..16)

Products under Development by Companies, H1 2016 (Contd..17)

Products under Development by Companies, H1 2016 (Contd..18)

Products under Development by Companies, H1 2016 (Contd..19)

Products under Development by Companies, H1 2016 (Contd..20)

Products under Development by Companies, H1 2016 (Contd..21)

Products under Development by Companies, H1 2016 (Contd..22)

Products under Development by Companies, H1 2016 (Contd..23)

Products under Development by Companies, H1 2016 (Contd..24)

Products under Development by Companies, H1 2016 (Contd..25)

Products under Development by Companies, H1 2016 (Contd..26)

Products under Development by Companies, H1 2016 (Contd..27)

Products under Development by Companies, H1 2016 (Contd..28)

Products under Development by Companies, H1 2016 (Contd..29)

Products under Development by Companies, H1 2016 (Contd..30)

Products under Development by Companies, H1 2016 (Contd..31)

Products under Development by Companies, H1 2016 (Contd..32)

Products under Development by Companies, H1 2016 (Contd..33)

Products under Development by Companies, H1 2016 (Contd..34)

Products under Development by Companies, H1 2016 (Contd..35)

Products under Development by Companies, H1 2016 (Contd..36)

Products under Development by Companies, H1 2016 (Contd..37)

Products under Development by Companies, H1 2016 (Contd..38)

Products under Development by Companies, H1 2016 (Contd..39)

Products under Development by Companies, H1 2016 (Contd..40)

Products under Development by Companies, H1 2016 (Contd..41)

Products under Development by Companies, H1 2016 (Contd..42)

Products under Development by Companies, H1 2016 (Contd..43)

Products under Development by Companies, H1 2016 (Contd..44)

Products under Development by Companies, H1 2016 (Contd..45)

Products under Development by Companies, H1 2016 (Contd..46)

Products under Development by Companies, H1 2016 (Contd..47)

Products under Development by Companies, H1 2016 (Contd..48)

Products under Development by Companies, H1 2016 (Contd..49)

Products under Development by Companies, H1 2016 (Contd..50)

Products under Development by Companies, H1 2016 (Contd..51)

Products under Development by Companies, H1 2016 (Contd..52)

Products under Development by Companies, H1 2016 (Contd..53)

Products under Development by Companies, H1 2016 (Contd..54)

Products under Development by Companies, H1 2016 (Contd..55)

Products under Development by Companies, H1 2016 (Contd..56)

Products under Development by Companies, H1 2016 (Contd..57)

Products under Development by Companies, H1 2016 (Contd..58)

Products under Development by Companies, H1 2016 (Contd..59)

Products under Development by Companies, H1 2016 (Contd..60)

Products under Development by Companies, H1 2016 (Contd..61)

Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..6)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..7)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..8)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..9)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..10)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..11)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..12)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..13)

Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016

Breast Cancer - Pipeline by 4SC AG, H1 2016

Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2016

Breast Cancer - Pipeline by AB Science SA, H1 2016

Breast Cancer - Pipeline by AbbVie Inc., H1 2016

Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2016

Breast Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016

Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016

Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016

Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016

Breast Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016

Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016

Breast Cancer - Pipeline by Aduro BioTech, Inc., H1 2016

Breast Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016

Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016

Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016

Breast Cancer - Pipeline by Advaxis, Inc., H1 2016

Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016

Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2016

Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016

Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2016

Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016

Breast Cancer - Pipeline by Affichem SA, H1 2016

Breast Cancer - Pipeline by Agenus, Inc., H1 2016

Breast Cancer - Pipeline by Agilvax, Inc., H1 2016

Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016

Breast Cancer - Pipeline by Alchemia Limited, H1 2016

Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016

Breast Cancer - Pipeline by Almac Discovery Limited, H1 2016

Breast Cancer - Pipeline by Alteogen Inc., H1 2016

Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016

Breast Cancer - Pipeline by Ambrx, Inc., H1 2016

Breast Cancer - Pipeline by American Gene Technologies International Inc., H1 2016

Breast Cancer - Pipeline by Amgen Inc., H1 2016

Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016

Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016

Breast Cancer - Pipeline by Angion Biomedica Corp., H1 2016

Breast Cancer - Pipeline by ANP Technologies, Inc., H1 2016

Breast Cancer - Pipeline by AntiCancer, Inc., H1 2016

Breast Cancer - Pipeline by Antigen Express, Inc., H1 2016

Breast Cancer - Pipeline by Antoxis Limited, H1 2016

Breast Cancer - Pipeline by Aphios Corporation, H1 2016

Breast Cancer - Pipeline by APIM Therapeutics AS, H1 2016 308List of Figures

Number of Products under Development for Breast Cancer, H1 2016

Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3-V Biosciences, Inc.
  • Biocon Limited
  • EnzymeBioSystems
  • ISU ABXIS Co.,Ltd.
  • Oncolix, Inc.
  • Sellas Inc.
  • MORE
Breast Cancer pipeline therapeutics constitutes close to 1127 molecules. Out of which approximately 921 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Breast Cancer - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Breast Cancer Breast cancer is a kind of cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. The risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. The symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 49, 143, 152, 2, 14, 464, 86 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 14, 1, 140 and 39 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
3-V Biosciences, Inc.
4SC AG
A&G Pharmaceutical, Inc.
AB Science SA
AbbVie Inc.
AbGenomics International, Inc.
Ability Pharmaceuticals, S.L.
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Adgero Biopharmaceuticals, Inc.
Aduro BioTech, Inc.
Advanced Accelerator Applications S.A.
Advanced Cancer Therapeutics
Advanced Proteome Therapeutics Corporation
Advaxis, Inc.
Advenchen Laboratories, LLC
Aegis Therapeutics, LLC
Aeglea BioTherapeutics, Inc.
Aerpio Therapeutics, Inc.
Aeterna Zentaris Inc.
Affichem SA
Agenus, Inc.
Agilvax, Inc.
Aileron Therapeutics, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Alteogen Inc.
Amarna Therapeutics B.V.
Ambrx, Inc.
American Gene Technologies International Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc.
Angion Biomedica Corp.
ANP Technologies, Inc.
AntiCancer, Inc.
Antigen Express, Inc.
Antoxis Limited
Aphios Corporation
APIM Therapeutics AS
arGEN-X BV
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
Arrien Pharmaceuticals, LLC
Asana BioSciences, LLC
Ascentage Pharma Group Corporation, Ltd.
AskAt Inc.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Athenex, Inc.
ATLAB Pharma SAS
Atossa Genetics, Inc.
Aurigene Discovery Technologies Limited
Ausio Pharmaceuticals, LLC
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Batu Biologics, Inc.
Bavarian Nordic A/S
Bayer AG
BCN Biosciences L.L.C.
BeiGene, Ltd.
Bellicum Pharmaceuticals, Inc.
Berg LLC
BerGenBio AS
Beta Pharma, Inc.
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
Biocon Limited
BioLite, Inc.
Bionomics Limited
Bionovis SA
BioNTech AG
Bioo Therapeutics
Biotecnol, Inc.
Biotest AG
Biscayne Pharmaceuticals, Inc.
Blirt S.A.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
BriaCell Therapeutics Corp.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Cancer Therapeutics CRC Pty Ltd
Cascadian Therapeutics Inc
CASI Pharmaceuticals Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Celprogen, Inc.
Celsion Corporation
Ceronco Biosciences
Cerulean Pharma, Inc.
ChemoCentryx, Inc.
Chiome Bioscience, Inc.
Chipscreen Biosciences Ltd
Cipla Ltd.
Clonz Biotech Private Limited
Clovis Oncology, Inc.
Coare Biotechnology, Inc.
CohBar, Inc.
Compliment Corporation
Corcept Therapeutics Incorporated
Cortice Biosciences, Inc.
Corvus Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CrystalGenomics, Inc.
Curadev Pharma Private Limited
Curadis GmbH
Curaxys, S.L.
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Debiopharm International SA
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
DexTech Medical AB
Diffusion Pharmaceuticals Inc.
Digna Biotech, S.L.
DiNonA Inc.
Dompe Farmaceutici S.p.A.
Dongkook Pharmaceutical Co., Ltd.
DormaTarg, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
EndoCeutics, Inc.
Endocyte, Inc.
EnGeneIC Ltd
Ensol Biosciences Inc.
EntreChem, S.L.
EnzymeBioSystems
EOS Biosciences, Inc.
Epigen Biosciences, Inc.
Esperance Pharmaceuticals, Inc.
eTheRNA Immunotherapies NV
Etubics Corporation
Eurofarma Laboratorios S.A.
Evgen Pharma Plc
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FibroStatin SL
FirstString Research, Inc.
Five Prime Therapeutics, Inc.
Forty Seven Inc.
G&E Herbal Biotechnology Co., Ltd.
G1 Therapeutics, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
Galena Biopharma, Inc.
GamaMabs Pharma S.A.
Ganymed Pharmaceuticals AG
Gene Techno Science Co., Ltd.
Genelux Corporation
Genenta Science s.r.l.
Genentech, Inc.
Genisphere Inc.
Genor BioPharma Co., Ltd.
Genoscience Pharma
Gero Corp
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GlycoMimetics, Inc.
Glycotope GmbH
Green Cross Corporation
GTx, Inc.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
HEC Pharm Co., Ltd.
Helix BioPharma Corp.
Hemispherx Biopharma, Inc.
Hetero Drugs Limited
Histogen, Inc.
HitGen LTD
Horizon Pharma Plc
Huabo Biopharm Co., Ltd.
Hutchison MediPharma Limited
Ideaya Biosciences Inc
Ignyta, Inc.
Immune Design Corp.
Immune Pharmaceuticals Inc.
ImmuneXcite, Inc.
Immunocore Limited
ImmunoFrontier, Inc.
Immunome Inc.
Immunomedics, Inc.
Immupharma Plc
IMPACT Therapeutics, Inc.
Imugene Limited
Incanthera Ltd.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Intas Pharmaceuticals Ltd.
Intica Biomedical, Inc.
Invictus Oncology Pvt. Ltd.
Io Therapeutics, Inc.
Ipsen S.A.
ISU ABXIS Co.,Ltd.
Jasco Pharmaceuticals, LLC.
JHL Biotech, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
JW Pharmaceutical Corporation
Jyant Technologies, Inc.
Kadmon Corporation, LLC
Kancera AB
Karyopharm Therapeutics, Inc.
Keystone Nano, Inc.
Kolltan Pharmaceuticals, Inc.
Komipharm International Co., Ltd.
Kyowa Hakko Kirin Co., Ltd.
La Jolla Pharmaceutical Company
Laboratoires Pierre Fabre SA
Laboratorio ELEA S.A.C.I.F. y A.
Laboratorios Farmaceuticos Rovi, S.A.
Lead Pharma Holding B.V.
LegoChem Biosciences, Inc
Les Laboratoires Servier SAS
Lipocure Ltd.
LondonPharma Ltd
Loxo Oncology, Inc.
Luye Pharma Group Ltd.
Lytix Biopharma AS
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Mateon Therapeutics Inc
MaxiVAX SA
Meabco A/S
Mebiopharm Co., Ltd.
MediaPharma s.r.l.
MedImmune, LLC
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Merus B.V.
MetaStat, Inc.
Millennium Pharmaceuticals Inc
Minerva Biotechnologies Corporation
Mithra Pharmaceuticals S.A.
Molecular Partners AG
Molecular Templates Inc.
Momenta Pharmaceuticals, Inc.
Monopar Therapeutics LLC
Morphotek, Inc.
MultiCell Technologies, Inc.
Multimmune GmbH
Mundipharma International Ltd
Mycenax Biotech Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
Nektar Therapeutics
Nemucore Medical Innovations, Inc.
Nerviano Medical Sciences S.r.l.
Netherlands Translational Research Center B.V.
NewLink Genetics Corporation
Nexigen GmbH
Nippon Kayaku Co., Ltd.
Northwest Biotherapeutics, Inc.
Novartis AG
Noviga Research AB
NuCana BioMed Limited
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Omeros Corporation
Omnitura Therapeutics Inc.
OncBioMune Pharmaceuticals Inc.
Oncobiologics, Inc.
Oncodrone BV
Oncogenex Pharmaceuticals, Inc.
Oncolix, Inc.
Oncolytics Biotech Inc.
Oncomatryx Biopharma, S.L.
OncoMax
OncoMed Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
OncoQR ML OG
OncoSec Medical Incorporated
OncoTartis, Inc.
OncoTherapy Science, Inc.
OncoVista Innovative Therapies, Inc.
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
OPKO Health, Inc.
Orega Biotech SAS
OSE Immunotherapeutics
Otsuka Holdings Co., Ltd.
Oxford BioTherapeutics Ltd
OXIS International, Inc.
Pacific Northwest Biotechnology, LLC
Panacea Biotec Limited
Panacea Pharmaceuticals, Inc.
Paras Biopharmaceuticals Finland Oy
PDS Biotechnology Corporation
PEP-Therapy SAS
Pfizer Inc.
Pharma Mar, S.A.
Pharma Two B Ltd
PharmAbcine, Inc.
Pharmacyclics, Inc.
PharmaCyte Biotech, Inc.
Pharmicell Co., Ltd.
Pharminox Limited
Phoenix Molecular Designs
Phylogica Limited
PIQUR Therapeutics AG
Pivot Pharmaceuticals Inc
Plantacor, Inc.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Premier Biomedical Inc.
Presage Biosciences, Inc.
Prescient Therapeutics Limited
Prima BioMed Ltd.
ProNAi Therapeutics, Inc.
Provectus Biopharmaceuticals, Inc.
Puma Biotechnology, Inc.
Qu Biologics Inc.
Quest PharmaTech Inc.
Radius Health, Inc.
Reata Pharmaceuticals, Inc.
Recepta Biopharma S.A.
Recombio S.L
Regen BioPharma, Inc.
Reliance Life Sciences Pvt. Ltd.
Repros Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
Rgenix, Inc.
Richter Gedeon Nyrt.
Rigontec GmbH
Sagetis Biotech, S.L.
Samyang Holdings Corporation
Sanofi
SATT IDF Innov
Savoy Pharmaceuticals, Inc.
Seattle Genetics, Inc.
SEEK Group
Sellas Inc.
Selvita S.A.
Senhwa Biosciences, Inc.
Sentinel Oncology Limited
Shanghai Henlius Biotech Co., Ltd.
Shenogen Pharma Group Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Shionogi & Co., Ltd.
Sigma-Tau S.p.A.
SignPath Pharma Inc
Sihuan Pharmaceutical Holdings Group Ltd.
Sillajen Biotherapeutics
Sinil Pharmaceutical Co., Ltd
Sirnaomics, Inc.
Soricimed Biopharma Inc.
Sorrento Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Sprint Bioscience AB
Starpharma Holdings Limited
Sun Pharma Advanced Research Company Ltd.
Supratek Pharma Inc.
Symic Biomedical, Inc.
Symphogen A/S
Syndax Pharmaceuticals, Inc.
Synergys Biotherapeutics, Inc.
Synta Pharmaceuticals Corp.
Synthon Holdings BV
Syros Pharmaceuticals, Inc.
Taiho Pharmaceutical Co., Ltd.
TaiRx, Inc.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
TapImmune Inc.
Tara Immuno-Oncology Therapeutics LLC
Terpenoid Therapeutics, Inc.
Tesaro, Inc.
Teva Pharmaceutical Industries Ltd.
The International Biotechnology Center (IBC) Generium
Theraclone Sciences, Inc.
Theravectys SA
Theryte Limited
Tiltan Pharma Ltd.
Tiziana Life Sciences Plc
Toko Pharmaceutical Industries Co., Ltd.
TRACON Pharmaceuticals, Inc.
Transcriptogen Ltd
Transgene Biotek Limited
TREAT U, S.A.
TVAX Biomedical, Inc.
Tyme Technologies, Inc.
UbiQ Bio BV
UbiVac, LLC
United BioPharma, Inc.
Vaccinex, Inc.
Vasgen Limited
Vault Pharma Inc.
Vaxil Bio Therapeutics Ltd.
Vaxon Biotech
VBS Pharmaceuticals
Verastem, Inc.
Vertex Pharmaceuticals Incorporated
VG Life Sciences, Inc.
ViiV Healthcare Limited
VioQuest Pharmaceuticals, Inc.
Viralytics Ltd.
ViroMed Co., Ltd.
Visionary Pharmaceuticals, Inc.
Vyriad
Wilex AG
WntResearch AB
XTuit Pharmaceuticals, Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd.
ZIOPHARM Oncology, Inc.
Zymeworks Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll